Hebrew University start-up wins Asper Prize for approach to cancer treatment
ViVac Pharma receives NIS 100,000 award for its work on programmable RNA immunotherapies targeting solid tumors.
Story
JPost.com - Business & Innovation · Israel
Join the conversation
Discuss the story with the TraceFeed community.
No comments yet. Be the first to add a perspective.